Mammography remains the technique of choice for the detection of early @entity0 . The sensitivity of mammography is 85%, but is decreased in @entity1 with dense breasts. Sestamibi scintimammography (SCM) has been suggested as an adjunctive modality to improve the detection of @entity0 . We conducted a study to determine the impact of SCM in @entity1 management. A prospective study was conducted in 95 @entity1 presenting with palpable masses and/or abnormal mammography scheduled for biopsy. Injection of 20-30 mCi of @entity1136 (Tc-99m) sestamibi into a pedal vein was performed. Ten-minute images of the breast and axilla were obtained in multiple projections. The mammography and SCM were correlated with pathology and clinical findings. The median age was 44 years (range 28-86 years). The total number of @entity75 was 104, as eight @entity1 had bilateral @entity75 and one @entity1 had two @entity75 in the same breast. Fifty-nine @entity1 presented with palpable @entity75 and 45 @entity1 with nonpalpable @entity75 (42 with abnormal mammography only and 3 with nipple discharge). A comparison of sensitivity, specificity, positive and negative predictive values, and overall accuracy of SCM and mammography were performed. The sensitivity and specificity for SCM were 83% and 83%, respectively, and for mammography were 65%, and 72%, respectively. The sensitivity and specificity for combined SCM and mammography were 87% and 94%, respectively. The p-value for mammography versus combined SCM and mammography was 0.0003 and that for SCM versus SCM and mammography was 0.0098. There were 80 (77%) benign and 24 (23%) malignant @entity75 . Of the 24 @entity5 , SCM missed six (25%), versus eight (33%) by mammography. In two @entity1 (9%) SCM detected malignancy in the breast that was not visualized by mammography or found on clinical examination. Sestamibi SCM improves the sensitivity of mammography and it detects up to 9% of @entity5 not detected by mammography or clinical examination. This testing could impact the management of 16,500 @entity1 in the United States every year. More studies are needed to better define its role in @entity0 detection.

@entity1136 sestamibi scintimammography complements mammography in the detection of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1136 :: ('MESH:D013667', 'Chemical') :: ['technetium-99m'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity75 :: ('MESH:D001927', 'Disease') :: ['lesions']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
